| Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. | |
MedLine Citation:
|
PMID: 20180126 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Flecainide is used as a pill-in-the-pocket treatment for pharmacological cardioversion in patients without structural heart disease and atrial fibrillation (AF). In patients with structural heart disease and elevated cardiovascular risk, flecainide is believed to be harmful. Therefore, data about safety and effectiveness of single-dose flecainide for cardioversion in patients at elevated cardiovascular risk are lacking. OBJECTIVES: One-hundred and six consecutive patients with recent onset AF and known structural heart disease and/or elevated PROCAM-score did receive oral flecainide 300 mg for cardioversion. METHODS: The effectiveness, safety and influencing factors of flecainide for cardioversion in high-risk patients were prospectively assessed. RESULTS: In 43 of 106 patients (40.6%), sinus rhythm could be restored within 192.4 +/- 10.7 min by flecainide. The PROCAM-score was 41.5 +/- 0.56 in patients with successful cardioversion compared to 45.7 +/- 0.74 in patients without successful cardioversion (P < 0.001). ACE-inhibitor co-medication was associated with a significantly lower rate of conversion by flecainide (HR 2.3, 95% CI, 1.12-4.26, P < 0.01). In 58 of 63 patients in whom cardioversion by flecainide was not effective, electrical cardioversion was performed which was successful in 47 patients. Life-threatening arrhythmias did not occur in any patient. The most common side effect was sinus-bradycardia and transient sinus arrest (2-4 s) immediately after conversion. CONCLUSIONS: When monitored properly, flecainide is safe and useful for cardioversion in patients at elevated cardiovascular risk. |
Authors:
|
Fikret Er; Orhan Aslan; Evren Caglayan; Natig Gassanov; Amir M Nia; Erland Erdmann; Stephan Rosenkranz |
Related Documents
:
|
2436916 - Holter monitoring in patients with mitral stenosis and sinus rhythm. 110126 - Occult thyrotoxicosis: a correctable cause of "idiopathic" atrial fibrillation. 361226 - Phase i clinical study of quelamycin. 12504636 - Relationship between the frequency of paroxysmal episodes of atrial fibrillation and pu... 9267976 - Serum angiotensin-converting enzyme in multiple sclerosis. 24189316 - Interpapillary muscle distance independently affects severity of functional mitral reg... |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2010-02-24 |
Journal Detail:
|
Title: Clinical research in cardiology : official journal of the German Cardiac Society Volume: 99 ISSN: 1861-0692 ISO Abbreviation: Clin Res Cardiol Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-26 Completed Date: 2010-09-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101264123 Medline TA: Clin Res Cardiol Country: Germany |
Other Details:
|
Languages: eng Pagination: 369-73 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine III, Heart Center of the University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. Fikret.Er@uk-koeln.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anti-Arrhythmia Agents / administration & dosage* Atrial Fibrillation / drug therapy, therapy* Electric Countershock* Female Flecainide / administration & dosage* Humans Male Risk Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 54143-55-4/Flecainide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Update on systemic therapies of metastatic renal cell carcinoma.
Next Document: The era of centers: the influence of establishing specialized centers on patients' choice of hospita...